Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, sequential dose escalation and expansion study to evaluate the safety,
tolerability, and pharmacokinetics of DS-8895a in Japanese subjects with advanced solid
tumors.